Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics that remove the plaques to slow cognitive decline in patients.

BrainScope is developing a novel biomarker for prediction of Alzheimer’s disease at its earliest stage in normal elderly with memory complaints.

Altoida, a leader in digital neuromarker diagnostics for neurological conditions, announced today the launch of its Scientific Advisory Board (SAB). The newly appointed experts will play a pivotal ...

Early diagnosis, treatment of bipolar disorder with the right medication, various therapies, lifestyle changes, and managing ...

Of course, there’s no actual engine and, for many G-advocates, a big part of the G’s appeal is the guttural throb of its four ...

A recent study published in Genomic Psychiatry has unveiled a promising new therapy that may help improve memory and reduce ...

Prescription digital therapeutics for mental health have the potential to increase patient access to care, but major barriers ...

The pharmaceutical industry, with its focus on cutting-edge research and holistic treatment approaches, will be instrumental in shaping the future of care for these interconnected conditions ...

Nu Skin Enterprises , a global beauty and wellness leader, today introduced MYND360, a new line of clinically proven nutritional formulas to support core needs for cognitive well-being. MYND360 is the ...

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...